Related Experiment Videos
[A new psychotropic drug: carpipramine, intermediate compound between 2 therapeutic classes]
L'Encephale
|January 1, 1977
Summary
Carpipramine, an open-label study drug, showed efficacy in treating schizophrenia, particularly hebephrenic and depressive subtypes, by stimulating psychomotor activity. It also aided in psychomotor deficits but did not act as an antidepressant.
Area of Science:
- Psychopharmacology
- Clinical Psychiatry
- Neuroscience
Background:
- Carpipramine is a neuroleptic agent with potential psychoanaleptic effects.
- Understanding its therapeutic profile across various mental disorders is crucial.
Purpose of the Study:
- To evaluate the efficacy and tolerance of carpipramine in hospitalized patients with diverse mental disorders.
- To assess its specific effects on schizophrenic symptoms and psychomotor deficits.
Main Methods:
- An open clinical study involving 100 hospitalized subjects.
- Therapeutic outcomes assessed globally and via a rating scale.
- Dose range: 50–400 mg/day.
Main Results:
- Carpipramine demonstrated significant efficacy in 66 schizophrenia cases, especially hebephrenic forms and depressive syndromes, by enhancing psychomotor activity.
- It was beneficial for psychomotor deficits in psychasthenia and opiate withdrawal.
- Aggravation was noted in paranoid schizophrenia and depersonalization anxiety.
- Excellent clinical and biological tolerance with rare extrapyramidal side effects.
Conclusions:
- Carpipramine acts as a potent desinhibitory neuroleptic with antidepressant-like psychoanaleptic effects.
- Its bipolar action may include antipsychotic properties at higher doses.
- Further research into its antipsychotic potential is warranted.